Volume | 272,267 |
|
|||||
News | - | ||||||
Day High | 0.77 | Low High |
|||||
Day Low | 0.6501 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
BioSig Technologies Inc | BSGM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.739 | 0.6501 | 0.77 | 0.661 | 0.73 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
881 | 272,267 | $ 0.7010532 | $ 190,874 | - | 0.2619 - 16.50 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:42:04 | formt | 100 | $ 0.66 | USD |
BioSig Technologies Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.44M | 9.33M | - | 286k | -27.27M | -2.92 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BioSig Technologies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BSGM Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.5181 | 0.77 | 0.4555 | 0.6340649 | 125,265 | 0.1419 | 27.39% |
1 Month | 0.75 | 0.78 | 0.4555 | 0.6215714 | 174,797 | -0.09 | -12.00% |
3 Months | 4.351 | 4.499 | 0.2619 | 1.04 | 476,678 | -3.69 | -84.83% |
6 Months | 5.078 | 6.80 | 0.2619 | 2.30 | 385,220 | -4.42 | -87.00% |
1 Year | 11.30 | 16.50 | 0.2619 | 7.65 | 452,583 | -10.64 | -94.16% |
3 Years | 43.20 | 49.00 | 0.2619 | 13.30 | 350,217 | -42.54 | -98.47% |
5 Years | 59.50 | 124.30 | 0.2619 | 37.41 | 372,917 | -58.84 | -98.89% |
BioSig Technologies Description
BioSig Technologiesis an advanced medical technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), BioSig is committed to addressing healthcare¿s biggest priorities-saving time, saving costs, and saving lives. The Company¿s first product, the PURE EP¿ System, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy. The global EP market is projected to reach $16B in 2028 with an 11.2% growth rate. |